Skip to main content

BIVI

Stock
Health Care
Biotechnology

Performance overview

BIVI Price
Price Chart

Forward-looking statistics

Beta
0.85
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Company info

SectorHealth Care
IndustryBiotechnology
Employees13
Market cap$26.3M

Fundamentals

Enterprise value-$5.6M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity1.68

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$13.30
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$807K
Avg trading volume (10 day)$880K
Put-call ratio—

Macro factor sensitivity

Growth-1.8
Credit+5.8
Liquidity+1.8
Inflation-7.8
Commodities-0.8
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio-0.22
Price to sales—
P/E Ratio-0.22
Enterprise Value to Revenue—
Price to book0.81

Upcoming events

Next earnings dayFebruary 13, 2024
Next dividend day—
Ex. dividend day—

News

Crude Oil Gains Over 1%; BioVie Shares Plunge

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday.

Benzinga (September 24, 2024)
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now

BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research (March 12, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free